clinical trial · NCT06603220
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Chronic Inducible UrticariaOral EVO756
brief summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
started
Aug 14, 2024
primary completion
May 8, 2025
completion
May 8, 2025
last updated
Jun 18, 2025
official title
An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol